ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)

NCT00229684 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

100

Enrollment

INDUSTRY

Sponsor class

Stopped The development program has been terminated

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Tesaglitazar
DRUG: pioglitazone

Sponsor

AstraZeneca